Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.6000
Nov 18 • 3:59 PM ET Dollar change-0.0299 Percentage change(-4.75%)
Aftermarket Close
0.6141
Aftermarket • 7:50 PM ET Dollar change+0.0141 Percentage change(2.35%)
Index
-
Market Cap
57.06M
Enterprise Value
26.07M
Income
-15.99M
Sales
0.00M
Book/sh
0.31
Cash/sh
0.33
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
14
IPO
Oct 08, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
1.95
P/C
1.81
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
6.68
Current Ratio
6.68
Debt/Eq
0.02
LT Debt/Eq
0.01
Option/Short
No / Yes
EPS (ttm)
-0.18
EPS next Y
-0.18
EPS next Q
-0.05
EPS this Y
40.62%
EPS next Y
2.63%
EPS next 5Y
4.35%
EPS past 3/5Y
24.09% 10.12%
Sales past 3/5Y
- -
EPS Y/Y TTM
62.99%
Sales Y/Y TTM
-
EPS Q/Q
31.01%
Sales Q/Q
-
Insider Own
8.11%
Insider Trans
0.00%
Inst Own
16.96%
Inst Trans
-0.59%
ROA
-40.90%
ROE
-48.60%
ROIC
-53.88%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-12.65%
SMA50
-26.91%
SMA200
-41.44%
Trades
Shs Outstand
95.10M
Shs Float
87.39M
52W High
1.81 -66.85%
52W Low
0.55 9.07%
Volatility
8.15% 8.31%
ATR (14)
0.05
RSI (14)
28.61
Beta
1.82
Rel Volume
0.73
Avg Volume
466.18K
Volume
340,297
Perf Week
-11.41%
Perf Month
-18.23%
Perf Quarter
-37.28%
Perf Half Y
-53.49%
Perf YTD
-55.56%
Perf Year
-60.53%
Perf 3Y
-41.75%
Perf 5Y
-94.40%
Perf 10Y
-
Prev Close
0.63
Price
0.60
Change %
-4.75%
Consensus
Strong Buy
Avg. Price Target
$3.33
Implied Upside
+455.0%
Analysts3incl. previous ratings
Rating Distribution2 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Dec 19, 2024Upgrade
RILY logoRB. Riley Securities
Neutral → Buy$1 → $1.50+150.0%
Jul 30, 2024Downgrade
CCantor Fitzgerald
Overweight → Neutral
Nov 03, 2021Initiated
OPY logoOOppenheimer
Outperform$22+3,566.7%
Nov 03, 2021Initiated
RILY logoRB. Riley Securities
Buy$27+4,400.0%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Doyle John BrendanChief Financial OfficerApr 16 '26Buy1.1310,00011,300627,509Apr 20 04:18 PM
Ricciardi LisaCEO & PresidentApr 16 '26Buy1.109,17510,0921,715,851Apr 20 04:16 PM
Caggiano AnthonyChief Medical OfficerApr 16 '26Buy1.1110,00011,100874,906Apr 20 04:15 PM
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer's disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.
CEOMs. Lisa Ricciardi
Chief Financial OfficerMr. John Brendan Doyle
Ph.D.Dr. Anthony O. Caggiano M.D.
VP & Head of CMCDr. Steven A. Weissman Ph.D.
Head of QualityMs. Anita Cornet